Rather than conducting reviews in silo, the FDA should consider all evidence, says vape lawyer. Read More
Tags :PMTA
Are choices key to successful switching?Read More
The FDA and the company are saying different things about Magellan’s application. Read More
How effective must a product be in helping adult smokers quit to overcome the theorized level of harm to youth?Read More
Neil McKeganey explains how companies can make the most of a recent ruling forcing the FDA to reconsider MDOs. Read More
A court ruling requires the agency to take a another look at six marketing applications.Read More
The FDA’s refusal to review marketing plans was error and not harmless (disagreeing with Fifth and DC Circuits).Read More
The FDA’s refusal to review marketing plans was error and not harmless (disagreeing with Fifth and DC Circuits).Read More
The FDA’s refusal to review marketing plans was error and not harmless (disagreeing with Fifth and DC Circuits).Read More
Despite onerous requirements on applicants, the agency was happy to cut its own paperwork.Read More
